Scenarios that move RNA
Atrium Therapeutics, Inc. - Common Stock
Scenarios that move RNA: 2 analyses, 0 positive, 2 negative.
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -12 · confidence low · horizon weeks
- · Satellos wins FDA IND clearance for Forazapadin in FSHD — ▼ · impact -20 · confidence low · horizon quarters